Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis

Table 3 Characteristics and outcome of tacrolimus therapy

Variable	n = 22
Intravenous initiation of tacrolimus treatment, n (%)	15/22 (68.2)
Duration of intravenous tacrolimus therapy (d, mean ± SEM)	4.0 ± 0.9 (range: 2-13)
Duration of tacrolimus therapy until discharge from the hospital or transfer to surgery (d, mean ± SEM)	15.9 ± 3.4 (n = 20)
Initial dose of intravenous tacrolimus (mg/24 h, mean ± SEM)	1.4 ± 0.4 (n = 15)
Initial dose of intravenous tacrolimus per body weight (μg/kg/24 h, mean ± SEM)	26 ± 3 (n = 15)
Initial dose of oral tacrolimus (mg/24 h, mean ± SEM)	5.3 ± 2.2 (n = 7)
Initial dose of oral tacrolimus per body weight (μg/kg/24 h, mean ± SEM)	95 ± 31 (n = 7)
Time to achievement of target tacrolimus trough level after intravenous treatment initiation (d, mean ± SEM)	3.1 ± 0.4 (n = 14)
Time to achievement of target tacrolimus trough level after oral treatment initiation (d, mean ± SEM)	4.2 ± 1.2 (n = 7)
Total duration of tacrolimus therapy to end of therapy or last follow-up (d, mean ± SEM)	128 ± 28.5 (range: 2-266)
Patients discharged from the hospital under continued tacrolimus therapy, n (%)	19/22 (86.4)
Clinical response to tacrolimus therapy, including remission, n (%)	18/22 (81.8)
Clinical remission under tacrolimus therapy, n (%)	8/22 (36.4)
Colectomy during follow-up, n (%)	7/22 (31.8)
Direct transmission to the surgery department after primary failure of tacrolimus therapy, n (%)	2/22 (9.1)
Time from start of tacrolimus therapy to colectomy (d, mean ± SEM)	97.4 ± 20.8 (range: 5-194)

SEM: Standard error of the mean.